Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc > Spceo has single handely moved THTX
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(201)
•••
Comment by palinc2000on May 07, 2022 7:32am
169 Views
Post# 34664199

RE:RE:Spceo has single handely moved THTX

RE:RE:Spceo has single handely moved THTX

We had a great dinner but did not overspent!

Actually my adjusted  cost base is below 2 CAD $ which means that I am in a profit situation but of course not as much as before...
Thank you for your Mothers Day wished.My wife and I have been blessed with 2 wonderful children and an unbelievable 9 grand kids!!!!!

 Of course  a grand slam with my THTX holdings would be great for the 15 of us ..... but not counting on it for day to day living and happiness


SPCEO1 wrote: I am sure the wife will be really happy to finally have you make some money on TH! Not sure I really had a role in it but glad for the happy outcome! Tell her I said Happy Mother's Day, if appropriate.
 

palinc2000 wrote: SP today!!!Made enough money today  just on todsy s purchase to take the wife to the best reataurant im town 
Thx




<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities